Sponsor: Daiichi Sankyo Pharma
Sponsor Study ID: DS6000-109
Study Title: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
CTO #: 104020
NCT Number:
Phase: II/III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Female Genital; Ovary
Study Objectives: To evaluate BICR- assessed ORR at each dose level of R-DXd. To evaluate investigator assessed ORR at each dose level of R-DXd. To evaluate the DoR at each dose level of R-DXd.